title: New updating into hemoglobinopathies.
abstract: Thalassemia and abnormal hemoglobin are the most common genetic disorders and are considered health problems in many developing countries. In the last few years, there has been much progress in laboratory diagnosis, treatment and control of thalassemia. The variation in the clinical severity in both α- and β-thalassemia reflects a genotype-phenotype interaction. This is important for future therapeutic intervention and should be well characterized in each population. The quality of life of the patients is much improved with regular blood transfusion and novel iron chelators. The cure for thalassemia is possible by stem cell transplantation and future gene therapy. It is expected that under multinational collaboration the prevention of thalassemia will happen worldwide.
authors: Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakornpathom, Thailand.
authors: S
authors: S
authors: Fucharoen
authors: Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakornpathom, Thailand.
authors: P
authors: P
authors: Winichagoon
mesh_terms: D001803:Blood Transfusion / Q000379:methods; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D005838:Genotype; D006453:Hemoglobinopathies / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D010641:Phenotype; D011788:Quality of Life; D033581:Stem Cell Transplantation / Q000379:methods / Q000639:trends; D013789:Thalassemia / Q000175:diagnosis / Q000235:genetics / Q000628:therapy
chemical_list: D007502:Iron Chelating Agents